<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507492</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-011</org_study_id>
    <secondary_id>2014-002392-28</secondary_id>
    <nct_id>NCT02507492</nct_id>
  </id_info>
  <brief_title>RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients</brief_title>
  <official_title>RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC)
      injection of RM-493, in subjects with POMC (propiomelanocortin) or other related rare genetic
      mutations, on body weight, metabolic function and blood pressure. Patients who respond during
      the initial 84 days of treatment can enter into long-term (2-year) extensions. The study drug
      (RM-493) will be administered in an unblinded fashion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of RM-493 on Body weight</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Change of body weight after Treatment with RM-493.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on metabolic serum parameters</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on metabolic serum parameters as measured by blood test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on blood pressure</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on blood pressure by daily blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on hunger</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on hunger as measured by the Global Hunger Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on body composition/Energy expenditure</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on body composition/Energy expenditure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on weight loss after treatment continuation of 2 years</measure>
    <time_frame>Day 1 through Day 730</time_frame>
    <description>Measurement of the effect of RM-493 on weight loss after treatment continuation of 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>RM-493 Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-493</intervention_name>
    <arm_group_label>RM-493 Once Daily</arm_group_label>
    <other_name>setmelanotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Homozygous or compound heterozygous (different gene mutation on both alleles) POMC,
             LEPR or PCSK1 gene mutation

          -  Obesity (BMI &gt; 30 kg/m2; + 2 BMI SDS)

          -  No other therapeutic option, which might cure the patient (e.g. bariatric surgery (see
             chapter 8))

          -  Negative Pregnancy test

          -  Highly effective contraception in women (defined as pearl index &lt; 1), if necessary
             also for partners of test persons)

          -  No participation in other clinical trials according to AMG (Arzneimittelgesetz) (2
             months before and after) at the time of this trial

          -  Normal or minimally elevated blood pressure (measured in 24RR monitoring or similar
             methods) according the guidelines of the ESH (European Society of Hypertension) and
             Deutsche Hochdruckliga: systolic &gt; 159 mmHg/diastolic 99 mmHg

          -  sufficient kidney and liver function (Creatinine, ALT, AST)

               -  normal values Alanine-Aminotransferase (ALT) (female): &lt; 31 U/l

               -  normal values Alanine-Aminotransferase (ALT) (male): &lt; 41 U/l

               -  normal values Aspartate-Aminotransferase (AST) (female &gt; 17 years): &lt; 35 U/l;
                  (female &lt; 17 years): 16- 46 U/l

               -  normal values Aspartate-Aminotransferase (AST) (male &gt; 17 years): &lt; 50 U/l; (male
                  &lt; 17 years): 16-46 U/l

               -  normal values bilirubins (male and female) up to 1,2 mg/dl

               -  normal values Creatinine (female &gt; 15 years): 0,51-0,95 mg/dl) ; (female &lt; 15
                  years): 0,46-0,77 mg/dl

               -  normal values Creatinine (male &gt; 15 years): 0,67 - 1,17 mg/dl) ; (male &lt; 15
                  years): 0,46-0,77 mg/dl

        Exclusion Criteria:

          -  Pregnancy or Breastfeeding

          -  All contraindications against study medication (including auxiliary substances)

          -  Interactions with study medication

          -  Participation of the patient in a clinical study within the last 2 months

          -  Intolerance against albumin

          -  Concomitant diseases, impaired organ functions, except for known, concurrent GI
             disorders or other clinical findings expected in PCSK1 or LEPR gene disorders

          -  Renal insufficiency (Creatinine &gt; 0,95 mg/dl (female), &gt; 1,17 mg/dl (male))

          -  Impaired liver function (Bilirubins &gt; 1.2 mg/dl)

          -  Neurological / psychiatric diseases

          -  HIV Infection

          -  Active Hepatitis B or C

          -  Melanoma or Melanoma occurrence in the family history

          -  Non-compliance

          -  Subjects who are legally detained in an official institution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susanna Wiegand, PD Dr.</last_name>
    <phone>+49 30 450 566887</phone>
    <email>susanna.wiegand@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Kühnen, Dr.</last_name>
    <phone>+49 30 450 450 666839</phone>
    <email>peter.kuehnen@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Wiegand, PD Dr.</last_name>
      <phone>+49 30 450 566887</phone>
      <email>susanna.wiegand@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Kühnen, Dr.</last_name>
      <phone>+49 30 450 450 666839</phone>
      <email>peter.kuehnen@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heiko Krude, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kühnen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>PD Dr. Susanna Wiegand</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>POMC, LEPR, PCSK1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

